OppenheimerFunds Inc. Has $135.31 Million Stake in Ionis Pharmaceuticals Inc (IONS)

OppenheimerFunds Inc. decreased its holdings in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,689,981 shares of the company’s stock after selling 18,426 shares during the quarter. OppenheimerFunds Inc.’s holdings in Ionis Pharmaceuticals were worth $135,306,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Rothschild Asset Management Inc. grew its position in shares of Ionis Pharmaceuticals by 10.8% during the 3rd quarter. Rothschild Asset Management Inc. now owns 281,068 shares of the company’s stock worth $14,250,000 after buying an additional 27,426 shares during the period. Candriam Luxembourg S.C.A. grew its position in shares of Ionis Pharmaceuticals by 30.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 143,000 shares of the company’s stock worth $7,250,000 after buying an additional 33,000 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Ionis Pharmaceuticals by 12.3% during the 3rd quarter. Envestnet Asset Management Inc. now owns 51,094 shares of the company’s stock worth $2,590,000 after buying an additional 5,594 shares during the period. AXA acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $5,202,000. Finally, California Public Employees Retirement System grew its position in shares of Ionis Pharmaceuticals by 1.6% during the 3rd quarter. California Public Employees Retirement System now owns 222,900 shares of the company’s stock worth $11,301,000 after buying an additional 3,600 shares during the period. Institutional investors own 91.01% of the company’s stock.

Ionis Pharmaceuticals Inc (NASDAQ IONS) opened at $49.88 on Friday. Ionis Pharmaceuticals Inc has a one year low of $37.26 and a one year high of $65.51. The firm has a market cap of $6,222.30, a P/E ratio of 332.40 and a beta of 2.53. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

In other Ionis Pharmaceuticals news, SVP Patrick R. O’neil sold 1,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $55.50, for a total value of $55,500.00. Following the transaction, the senior vice president now owns 11,433 shares of the company’s stock, valued at $634,531.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Elizabeth L. Hougen sold 2,724 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $51.76, for a total transaction of $140,994.24. Following the completion of the transaction, the chief financial officer now directly owns 17,224 shares in the company, valued at approximately $891,514.24. The disclosure for this sale can be found here. Insiders have sold a total of 124,635 shares of company stock worth $6,482,681 in the last three months. 2.13% of the stock is owned by insiders.

Several brokerages have recently commented on IONS. Sanford C. Bernstein reiterated a “market perform” rating and set a $55.00 price target (down previously from $61.00) on shares of Ionis Pharmaceuticals in a research report on Tuesday. Morgan Stanley lifted their price target on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 8th. BMO Capital Markets lifted their price target on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. BidaskClub lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. Finally, Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Four research analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $50.62.

ILLEGAL ACTIVITY NOTICE: “OppenheimerFunds Inc. Has $135.31 Million Stake in Ionis Pharmaceuticals Inc (IONS)” was published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://weekherald.com/2018/02/23/oppenheimerfunds-inc-has-135-31-million-stake-in-ionis-pharmaceuticals-inc-ions.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply